Helicobacter pylori infection as a protective factor for glue extrusion bleeding

Abstract

Abstract: Objective To investigate the relationship between glue extrusion bleeding and helicobacter pylori (Hp) infection.Methods The a retrospective study enrolled 524 patients with endoscopic tissue adhesive injection in our hospital from October 2008 to June 2017.including 64 cases of glue extrusion bleeding group and 460 cases of non-bleeding group. Hp infection rate was compared between the two groups. Results There were 430 Hp positive patients with infection rate of 82.06%, 64 patients suffering glue extrusion bleeding with an incidence rate was of 12.21%. The Hp infection rate in non-bleeding group was significantly higher than that in bleeding group (P=0.00). Hp infection was not a risk factor for glue extrusion bleeding (P=0.130).Bleeding rate was higher in patients with poor liver reserve function.Conclusion Hp infection might be a protective factor for patients with gastric variceal who underwent endoscopic tissue adhesive injection. Additionally,the glue extrusion bleeding incidence has a positive correlation with Child-Pugh score.

Key words: Helicobacter pylori, Glue extrusion bleeding, Gastroesophageal varices, Liver cirrhosis

LIN Yi-jun, MA Jia-li, ZHOU Yu-lin, HU Ju-long, LIANG Xiu-xia, LI Ping.. Helicobacter pylori infection as a protective factor for glue extrusion bleeding[J]. Chinese Hepatolgy, 2018, 23(2): 118-120.

References

[1] Koziel S, Kobryń K, Paluszkiewicz R, et al. Endoscopic treatment of gastric varices bleeding with the use of n-butyl-2 cyanoacrylate. Prz Gastroenterol,2015,10: 239-243.
[2] Poddar U, Borkar V, Yachha SK, et al. Endoscopic management of bleeding gastric varices with N-butyl.2-cyanoacrylate glue injection in children with non-cirrhotic portal hypertension. Endosc Int Open,2016,4: E1063-E1067.
[3] 令狐恩强,杨玉秀,刘吉勇,等.消化道静脉曲张及出血的内镜诊断和治疗规范试行方案(2009年).中华消化内镜杂志,2010,27: 1-4.
[4] Joo HS, Jang JY, Eun SH, et al. Long-term results of endoscopic histoacry(N-butyl-2-cyanoacrylate)injection for treatment of gastric varices—a 10-year experience. Korean J Gastroenteral,2007,49:320-356.
[5] Ni Z,Chen H,Tang S,et al.The efficacy and the safety of prophylactic N-butyl-2-cyanoacrylate injection for gastric varices using a modified injection technique.Surg Laparosc Endosc Percutan Tech,2016.26: e85-90.
[6] 马佳丽,李坪,周玉玲,等.胃静脉曲张内镜下组织粘合剂注射治疗后排胶出血临床观察.肝脏,2016,21: 1033-1034.
[7] Sakamoto Y, Oho K, Toyonaqa A, et al. Effect of helicobacter pylori infection on esophagogastric variceal bleeding in patients with liver cirrhosis and portal hypertention.J Gastroenterol Hepatol,2013,28: 1444-1449.
[8] Asaka M, Suqivama T, Nobuta A, et al. Atrophic gastritis and intestinal metaplasia in Japan:results of a large multicenter study.Helicobacter,2001,6: 294-299.
[9] Huang J, Cui J. Evaluation of helicobacter pylori infection in patients with chronic hepatic disease.Chin Med J,2017,130: 149-154.
[10] Licinio R, Losurdo G, Carparelli S, et al. Helicobacter pylori, liver cirrhosis, and portal hypertension: an update appraisal.Immunopharmmacol immunotoxicol,2016,27:1-6.
[11] Chang SS, Hu HY. H. pyloi eradication lower ulcers in cirrhosis. J Dig Dis,2014,15: 451-458.
[12] Takuma Y. Helicobacter pylori infection and liver diseases.Gan To Kagaky Ryoho,2011,38: 362-364.
[13] Esmat G,El-Bendary M,Zakarya S,et al.Role of helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with oe without heaptocellular carcinoma:possible association with disease progression.J Viral Hepat,2012,19:473-479.
[14] Castera L,Pedeboscq A,Rocha M, et al.Relationship between the sevierity of hepatitis C virus-related liver disease and the presence of helicobacter species in the liver:a prospective study. World J Gastroenterol, 2006,12: 7278-7284.

[1]	HU Hua-hua, LIU Jun, GUAN Li-yu, XU Jie-hong, YI Hong, LI Zhong-zhuan, QIN Shu-fen, DENG Xiang-yu. Hemodynamic analysis of liver cirrhosis complicated with esophageal and gastric varices rupture [J]. Chinese Hepatolgy, 2020, 25(4): 369-371.
[2]	LI Xiu-lan, LIU Qing, RAN Ran. Clinical observation of hysteroscopic surgery in patients with decompensated liver cirrhosis [J]. Chinese Hepatolgy, 2020, 25(4): 365-368.
[3]	ZHUANG Yan, LU Jie, XIE Qing, LIN Lan-yi.. Study on the current status of Direct-acting antiviral Treatment in Chinese patients with HCV-related liver cirrhosis [J]. Chinese Hepatolgy, 2020, 25(3): 249-253.
[4]	KONG Yuan-yuan, WEI Wei, SHAN Shan, MA Hong, OU Xiao-juan, XU Xiao-yuan, DUAN Zhong-ping, HOU Jin-lin, WEI Lai, YOU Hong, JIA Ji-dong, CR-HepB Group. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis [J]. Chinese Hepatolgy, 2020, 25(2): 123-127.
[5]	MENG Qing-yang, XU Chun-lin, KANG Peng. Ox-LDL-induced ETs production of macrophages in patients with cirrhosis [J]. Chinese Hepatolgy, 2019, 24(9): 1007-1010.
[6]	QIAN Rong, YANG Wei-zhong. Evaluation the hemodynamics of middle cerebral artery in patients with liver cirrhosis by transcranial Doppler ultrasound combined with breath-holding test [J]. Chinese Hepatolgy, 2019, 24(8): 861-863.
[7]	XU Qiang, MA Yan, GUO Feng, WANG Xiao-bo, WANG Xiao-zhong. Analysis of risk factors for 30-day death of cirrhosis-associated acute kidney injury [J]. Chinese Hepatolgy, 2019, 24(8): 857-860.
[8]	SHU Dan, HUANG Xiang-rong, JIANG Yu-jin, HUANG Ting, LIU Ying-xia, XU Cheng.. Logistic regression analysis of risk factors for portal vein thrombosis in liver cirrhosis [J]. Chinese Hepatolgy, 2019, 24(7): 740-743.
[9]	ZHANG Jun-chang, XU Biao, KUANG Zhi-dan, MOU Jin-song. Efficacy analysis of ascites drainage in 25 patients with liver cirrhosis complicated with intra-abdominal hypertension under bladder pressure monitoring [J]. Chinese Hepatolgy, 2019, 24(5): 497-498.
[10]	HU Xing, MENG Fan-kun, HAN Jing, ZUO Qiao. Evaluation of the cardiac function in patients with liver cirrhosis by tissue Doppleimag Tei index [J]. Chinese Hepatolgy, 2019, 24(3): 239-242.
[11]	WANG Dan, MU Jin-song, HU Zhi-jun, YAN Bing-bing, KUANG Zhi-dan. Prognostic risk factors in patients with cirrhosis and cerebral hemorrhage [J]. Chinese Hepatolgy, 2019, 24(10): 1116-1118.
[12]	ZHANG Zhen, WANG Meng-long, ZHANG Hai-tao, ZHANG Qi-kun, LIU Fu-quan. Risk factors for early portal venous system thrombosis after devascularization with splenectomy and portal hypertension in cirrhotic patients with portal hypertension and preventive effects of blood activating, anticoagulation and antiplatelet therapy [J]. Chinese Hepatolgy, 2019, 24(1): 24-27.
[13]	XIONG Jing-ping, LIU Hai-ying, ZHANG Yue-xin. Analysis of risk factors for portal vein thrombosis in liver cirrhosis patients [J]. Chinese Hepatolgy, 2018, 23(3): 206-209.
[14]	LIU Jin-jin, DING Rui, OU Xiao-juan, WU Xiao-ning, JIA Ji-dong. A clinical study on the predictors for esophageal variceal rebleeding in patients with liver cirrhosis after endoscopic variceal ligation treatment [J]. Chinese Hepatolgy, 2018, 23(12): 1065-1068.
[15]	ZHUANG Yan, WANG Xiao-lin, LIU Ke-hui, XU Yu-min, XIE Jin-dong, LIN Zhi-mei, WANG Hui, XIE Qing, GUO Qing. Clinical characteristics and significance of plasma von Willebrand factor antigen level and VITRO score in Chinese patients with various hepatic diseases [J]. Chinese Hepatolgy, 2018, 23(1): 14-17.